Expression of mdrl and gst-π in human breast tumours: Comparison to in vitro chemosensitivity

93Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Increased expression of the mdrl gene, encoding the 175 kDa P-glycoprotein, and the gst-n gene, encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin. In this present study we have measured RNA levels of mdrl and gst-π in primary human breast tumour biopsies prior to chemotherapy and from tumours which have different inherent responses to doxorubicin treatment, including colon, head and neck squamous cell carcinomas and myeloid leukaemias. Detectable levels of mdrl mRNA was observed in 25 out of 49 breast tumours, with up to a 100-fold range in expression. A narrower range of gst-π expression has also been observed in these tumours. Chemosensitivity of cells grown in short-term culture from some of the breast tumours has been measured by an in vitro colony forming assay in the presence of doxorubicin. Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID501) with RNA levels showed that the tumours with high mdrl expression had high ID50, while the more sensitive explants had low mdrl expression. These results support a role for mdrl gene expression in determining the response of human breast cancer cells to chemotherapy. © The MacMillan Press Ltd., 1990.

Cite

CITATION STYLE

APA

Keith, W. N., Stallard, S., & Brown, R. (1990). Expression of mdrl and gst-π in human breast tumours: Comparison to in vitro chemosensitivity. British Journal of Cancer, 61(5), 712–716. https://doi.org/10.1038/bjc.1990.160

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free